

CSD/BSE&NSE/CC/2025-26
May 19, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Schedule of Conference Call for Investors

With reference to above subject, please find enclosed intimation regarding schedule of conference call for investors on Wednesday, May 28, 2025 at 06.15 p.m. IST to discuss the Audited Financial Results for the Q4 & FY25, to be considered on May 28, 2025.

This is for your information and record.

Thanking You.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com




Cohance Lifesciences (formerly Suven Pharmaceuticals) Limited's Q4 & FY25 Results Conference Call on Wednesday, May 28, 2025, at 6.15 pm IST.

Cohance Lifesciences Ltd., will organize a conference call for investors and analysts on Wednesday, May 28, 2025 at 6.15 pm IST.

The management team will be represented by Mr. Vivek Sharma (Executive Chairman), Dr. V Prasada Raju (Managing Director), Dr. Sudhir Kumar Singh (Chief Executive Officer), Mr. Himanshu Agarwal (Chief Financial Officer) & Cyndrella Carvalho (Head – IR).

The conference call will be initiated with a brief management discussion on the Q4 & FY25 results to be declared on Wednesday, May 28, 2025 followed by an interactive Question & Answer session.

Details of the conference call are as follows:

Timing	6.15 pm IST on Wednesday, May 28, 2025
Conference dial-in	
Primary number	+91 22 6280 1141 / +91 22 7115 8042
Singapore Toll Free Number	800 101 2045
Hong Kong Toll Free Number	800 964 448
USA Toll Free Number	1 866 746 2133
UK Toll Free Number	0 808 101 1573
Pre-registration	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link:</p> <div>  Click here to ExpressJoin the Call </div> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call</p>

Please dial the above number 5-10 minutes prior to the scheduled start to ensure that you are connected to the call on time.

For more information, please contact:

Cyndrella Carvalho, Head - Investor Relations,
Cohance Lifesciences Limited
Tel: 040 2354 3311
Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar
CDR India
Tel: +91 98206 37649/ +91 77770 35061
Email: gavin@cdr-india.com
rishab@cdr-india.com

Cohance Lifesciences Limited
 (Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
 Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
 Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com